14-15 September 2015, London, UK

www.globalengage.co.uk/precision-medicine.html

The 2nd Precision Medicine Congress

ENABLING SUCCESSFUL IMPLEMENTATION THROUGH BIOMARKER, CDx, GENOMIC AND BIG DATA RESEARCH

Following on from the success of the inaugural meeting which attracted over 150 key senior attendees, Global Engage is pleased to announce the 2nd Precision Medicine Congress which will be held on September 14-15, 2015 in London, UK at the London Heathrow Hotel. The meeting is part of our successful Drug Discovery series which includes innovative meetings on Digital Health, Digital Pathology, Human Microbiome, Synthetic Biology, qPCR/ dPCR, & Biologics among others. www.globalengage.co.uk/events/

Recent advancements in the biomarker, CDx genomic and big data space have meant that some of the fundamental challenges of precision medicine are being realised. The potential for personalized medicine and therefore the possibility of delivering superior outcomes for patients is in reach. There is, however, a lot more to do. Alongside the continued developments in science as well as improvements in clinical trial design, support mechanisms such as market access /reimbursement/ regulatory strategies need to be further developed. Continued work by all stakeholders is therefore vital for success.

The congress has been purposely designed for a variety of audiences from drug and DX developers, payers, healthcare providers, academics to technology solution providers.

Attracting experts working in all areas of precision and personalised medicine such as biomarkers, CDx, translational medicine, clinical trials, genomics, NGS, bioinformatics and health economics, this two day interactive meeting will provide you the opportunity to take home cutting edge strategies, case study examples and methods to allow you to both implement and take the vital next steps in delivering precision medicine. This will be achieved through a vibrant exhibition room full of technology providers showcasing their technologies and other solutions, expert led case study presentations and interactive Q&A panel discussions examining topics during four separate tracks covering the areas below.

Confirmed Speakers Include:

Leroy Hood
President, Institute of Systems Biology

Richard Barker
Chairman of the Precision Medicine Catapult, founding Director of CASMI

Martina Kaufman
Managing Director, Martina Kaufmann Consulting

Menelas N Pangalos
EVP, Innovative Medicines & Early Development, AstraZeneca

Conference Synopsis

Day 1 Stream 1
Strategies & Technologies to Enable Successful Implementation of Precision Medicine

- Precision Medicine approaches – Taking the next steps
- Deliver superior outcomes for patients through precision Medicine
- Economics for precision medicine - Adding value
  - Incentivising pricing &reimbursement strategies
  - Market access considerations
- IP concerns / Regulations - US & European differences
- Adaptive Licensing
- Ethical &regulatory implications of individualizing medicine
- Biomarker discovery, development & validation strategies
- Innovative clinical trials
- Technologies to enable Precision Medicine
- Panel Discussion –Future of Precision Medicine

Day 1 Stream 2
Precision Medicine Therapeutic Case Studies

- Biomarker Case Studies
- Oncology, CNS, Immunology, Respiratory etc
- Create targeted treatments based patients' genetic profiles
- Multiplexed assays for cancer development
- Tumour heterogeneity
- Oncology / CNS CDx strategies
- CNS Diagnostic Imaging

Day 2 Stream 1
Biomarker & Companion Diagnostics Development to Deliver Precision Medicine

- Delivering a successful biomarker strategy alongside developing a companion diagnostic
- CDx strategies and accelerating development
- Choosing a CDx platform
- Commercialization of CDx
- Diagnostic regulation in personalised medicine
- Biomarker Identification technologies
- Molecular profiling technologies
- Panel Discussion – Choosing & Managing Rx-Dx Partnerships

Day 2 Stream 2
Integrating Personal Genomics, Big Data and Bioinformatics

- Integrating data into personalised medicine decision making
- Linking NGS / microarray/ other technologies to the bedside
- Preventive precision medicine
- Analyzing genetic mutation
- Effective data interpretation and clinical decision support
- Clinical biomarker data analysis
- Successful collection storage and analysis of data
- Big data analytics – Big data into useful data
- Biobanking
- Panel Discussion: Big Data, Technologies &Methods to Improve Data Integration for Precision Medicine

Confirmed Speakers

Marvin Caruthers, Distinguished Professor of Chemistry and Biochemistry, University of Colorado

Baitang Ning, Division of Systems Biology, NCTR/FDA

Andreas Wallnöfer, Senior Vice President, pRED – Roche Pharma Research & Early Development, F. Hoffmann-La Roche

Ketan Patel, Product Strategist Precision Medicine, Oracle Health Sciences

Thomas Skøt Jensen, CEO and co-founder, Intomics

Vic Weigman, Associate Director of Translational Genomics, EA | Quintiles

Tom Halsey Associate Director of Genomic Research and Development, EA | Quintiles

George Vasmatzis, co-director, Biomarker Discovery Program, Center for Individualized Medicine, Mayo Clinic

Robin Sherrington, SVP, Business & Corporate Development, Xenon Pharmaceuticals Inc

Tony Bartlett, Director, European Commercial Operations & Collaborations, SomaLogic, Inc.

Therese Koal, Biocrates Life Sciences AG, Head of R&D, Biocrates Life Sciences

Farideh Bischoff, Executive Director of Scientific Affairs, SiliconBiosystems

Senior Representative, Ferrer inCode

Jonathan Lewis, CEO and Chairman, Molecular Ninja Therapeutics, USA

Niven Narain, Co-Founder, President & CTO, Berg Pharma

Elaine Kilgour, Associate Director, Oncology Translational Science, AstraZeneca

Krishna Kalari, Assistant Professor of Medical Informatics, Department of Health Sciences Research, Mayo Clinic



Hans Lerach, Professor, Max Planck Institute for Molecular Genetics, Germany

Liz Milward, A./Professor, Deputy President Academic Senate (Research), School of Biomedical Sciences and Pharmacy, University of Newcastle, Australia

Andres Metspalu, Professor and Director Estonian Genome Center, University of Tartu, Estonia

Thomas Metcalfe, Project Leader, Roche Pharma Regulatory

Dr. Andrea Ballagi, VP Sales and Marketing, Olink Bioscience

Joseph M Beechem, Sr. V.P. of Research and Development, NanoString Technologies INC

Bob Holt, Molecular Genetic Services Manager, Tepnel Pharma Services

Senior Representative, Covance

Nicole St Jean, Corporate Business Development, Global Product & Portfolio Strategy, AstraZeneca

Miro Venturi, Global Head Diagnostic Biomarkers, Roche

Slava Akmaev, Chief Analytics Officer, Senior Vice President, Berg Pharma

Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting

Thomas Wilckens, CSO & Founder, InnVentis

Felix Frueh, Chief Scientific Officer, Human Longevity, Inc
Andreas Wallnöfer, Senior Vice President, pRED
F. Hoffmann-La Roche

Jennifer Dudinak, Vice President, Global Regulatory Affairs, Head, Pharma Regulatory Therapeutic Team, GlaxoSmithKline, Research and Development

Alain van Gool, Professor, Head Biomarkers in Personalized Healthcare, TNO, Radboud University Medical Center

Gil Alterovitz, Assistant Professor, Harvard Medical School Director, BCL Faculty, CHIP, Boston Children's Hospital

David M Jackson, VP - Diagnostics / Companion Diagnostics, Arno Therapeutics, Inc

Xuemei Zhao, Principal Scientist, Translational Biomarkers Merck

Mark Caulfield, Professor, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London & Chief Scientist, Genomics England

Sponsors, Supporters and Media Partners

Platinum Sponsors

intomics – from data to biology

nanoString TECHNOLOGIES

Gold Sponsors

eagle genomics

Tepnel Pharma Services

Silver Sponsors

COVANCE – SOLUTIONS MADE REAL™

ferrer inCode

silicon biosystems – A MENARINI GROUP COMPANY

SomaLogic

Sponsors

ANGLE

BIOCRATES LIFE SCIENCES – The Deep Phenotyping Company

GenomicsNet

MYRIAD

OLINK BIOSCIENCE

ORACLE HEALTH SCIENCES

ea | QUINTILES

NPC NATIONAL PHENOME CENTRE

MRC-NIHR National Phenome Centre

Roche

sysmex

Unilabs

Media Partners

BENTHAM SCIENCE

GBi

MARKETSANDMARKETS

RR MARKET RESEARCH

pharmaphorum – bringing healthcare together

Venue

London Heathrow Marriott Hotel
Bath Road
Hayes
UB3 5AN
United Kingdom

A special rate will be available on registration.

For more information please visit our website for details - www.globalengage.co.uk/precision/venue.html

Agenda Day One – Monday 14th September 2015

8.00-08.50	**Registration & Coffee**
08.50-09.00	Welcome Address – County Hall Room Track Chair - **Thomas Wilckens, CSO & Founder, InnVentis**
09.00-09.40	Keynote Address **Proactive P4 Medicine: Catalyzing a Revolution in Healthcare through a Longitudinal, High-dimensional Data Study of 100,000 Person Wellness Project** Systems medicine has reached a tipping point and is already beginning to transform the practice of medicine. Three converging opportunities—systems medicine, big data (and its analytics) and patient-activated social networks—are leading to a proactive medicine that is predictive, personalized, preventive and participatory (P4). P4 medicine has two central thrusts—quantifying wellness and demystifying disease. I will contrast P4 medicine with contemporary evidence-based medicine and discuss its societal implications for healthcare. I will discuss how we plan to introduce P4 medicine into the current healthcare system with a P4 pilot program—a longitudinal, high-dimensional data cloud study on 100,000 well patients. We have already generated and analyzed the dynamical data clouds for a year on 105 well individuals. The preliminary results frzom these studies are striking. This approach can be used to study any disease—and I will give several illustrations including Alzheimer's Disease. These advances will have profound implications for healthcare and society. Confirmed: **Leroy Hood, President, Institute of Systems Biology, USA**
09.40-10.20	Keynote Address **Harnessing the Power of Genomics to Deliver the Promise of Personalised Healthcare** Personalised healthcare (PHC) is an integral part of our R&D activities at AstraZeneca. Today more than 80% of our clinical pipeline has a PHC component and our teams have already demonstrated what genomic science can do across our oncology portfolio. However, we know that this is only the start. This is why we are working collaboratively with our industry and academic partners to harness the latest breakthroughs in genomic science that will enable us to deliver the next generation of precision medicines and companion diagnostics with the potential to transform the lives of patients around the world. Confirmed: **Menelas N Pangalos, EVP, Innovative Medicines & Early Development, AstraZeneca**
10.20-10.50	**Solution Provider Presentation** **Biomarker Development for Immuno-Oncology and Cancer immunotherapy: Simultaneous Digital Counting of Nucleic-Acids and Proteins at 800-Plex** The ability of mutated cells to give rise to cancer relies upon the ability to evade immune recognition, suppress immune activity, and persist in a chronically inflamed environment. NanoString has developed an all-digital cancer immune-profiling technology that simultaneously measures 770 mRNA's (24 infiltrating immune cell types plus extensive immune-signaling pathways) plus 30 key IO proteins (including PD-1, PD-L1, CTLA4, OX40) using small amounts of clinically relevant samples (~ 50,000 PBMCs for mRNA+protein, 1 or 2, 5um slices for mRNA alone). This technology forms the basis for multi-year collaborations between NanoString and MD Anderson and the Cancer Immunotherapy Trials Network (CITN) to discover multi-analyte-type (mRNA + protein) biomarker signatures to guide cancer immunotherapy. NanoString gene expression profiling has also been highlighted by Merck (e.g., poster # 6017, ASCO 2015) to select patients that will benefit from anti-PD1 based therapy (Keytruda). This technology is being expanded to FFPE slices. Confirmed: **Joseph M Beechem, Sr. V.P. of Research and Development, NanoString Technologies INC**
10.50-12.00	**Morning Refreshments** **Poster Presentation Sessions** **One to One Meetings**

	Strategies & Technologies to Enable Successful Implementation Of Precision Medicine **County Hall Room**	**Precision Medicine Therapeutic Case Studies** **Marble Arch**
	Track Chair - **Thomas Wilckens, CSO & Founder, InnVentis**	Track Chair - **Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting**
12.00-12.30	**The Advent of Big Data in Health Care and How it Will Shape the Future of Personalized Medicine** • New technologies in next generation sequencing and big data computing are enabling the discovery, development, and application of new insights into clinical practice • These insights are based on the analysis of data derived from n of millions, but allow extrapolation and determination of what might be the best treatment for n of one • The creation of vast databases, as seen in many private as well as public efforts over the last few years is building the infrastructure needed for the future of a more precise and more personal approach to medicine. Confirmed **Felix Frueh, Chief Scientific Officer, Human Longevity, Inc**	**Precision Medicine in Oncology - Opportunities and Challenges** • Why current concepts of biomarker development will be challenged within the future paradigm • Inftrastructure, policy and framework hurdles to realizing the promise of Precision Medicine in Oncology Confirmed: **Thomas Metcalfe, Project Leader, Roche Pharma Regulatory**

12.30-13.00	**Partnership Between Industry and Academia in Exploratory Clinical Research** • The majority of new mechanisms and drugs are emerging from biotech or academic groups • The translation of promising research assets into the clinical setting is the bottleneck in R&D • New models of collaborations need to be explored and experimented, driven from both sides to address the needs of academia, industry and public healthcare. Confirmed: **Andreas Wallnöfer, Senior Vice President, pRED – Roche Pharma Research & Early Development, F. Hoffmann-La Roche**	**Clinical development of Arno's lead oncology drug and companion diagnostic** Confirmed: **David M Jackson, VP - Diagnostics / Companion Diagnostics, Arno Therapeutics, Inc**
13.00-13.30	**Solution Provider Presentation** **Metabolic Phenotyping in Translational Medicine – Ready for Routine!?** Confirmed: **Therese Koal, Biocrates Life Sciences AG, Head of R&D, Biocrates Life Sciences** **Sponsored by Biocrates** BIOCRATES LIFE SCIENCES The Deep Phenotyping Company	**Solution Provider Presentation** **Start With the End in Mind – A Diagnostic Company's Perspective on Companion Diagnostic Development,** Confirmed: **Bob Holt, Molecular Genetic Services Manager, Tepnel Pharma Services** **Sponsored by Tepnel Pharma Services** Tepnel Pharma Services
13.30-14.30	**Lunch** **One to One Meetings**	
14.30-15.00	**Title to be Confirmed** Confirmed: **Mark Caulfield, Professor, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London & Chief Scientist, Genomics England**	**Implementation of FISH based selection of FGF-receptor amplified patients for treatment with our FGFR inhibitor AZD4547.** • Examples of recent patient selection approaches in AstraZeneca oncology • Focus on lessons learned from FGFR project experience including: • Hypothesis development in preclinical models • Clinical implementation including highlighting the challenges of implementing prospective screening for low prevalence patient populations in clinical studies • Analysis of the actual trial population wrt FGFR gene amplification, expression and comparison to preclinical models • Discussion of the challenge that tumour heterogeneity present for the selection of amplified pts by FISH and one approach to assessing intra-tumoural heterogeneity by automated image analysis of FISH Confirmed: **Elaine Kilgour, Associate Director, Oncology Translational Science, AstraZeneca**
15.00-15.30	**Title to be Confirmed – Market Access** Reserved: **Iain Miller, Founder, Healthcare Strategies Group & Member, Technology Appraisal Committee, NICE**	**Title to be Confirmed** Confirmed: **Robin Sherrington, SVP, Business & Corporate Development, Xenon Pharmaceuticals Inc**

15.30-16.00

Solution Provider Presentation
Using DNA Sequencing to Identify Responding Patients

- Next Generation Sequencing (NGS) data holds great promise as a powerful tool for patient stratification, but important obstacles in using and interpreting NGS data for personalised medicine needs to be overcome.
- Main obstacles include incomplete biological knowledge, interpretation of functional impact of genetic variants, how different genetic variants and mutations collectively impact biological systems, and how predictive genetic variants are identified when there is only access to small patient numbers, e.g. in clinical trials.
- Integrative analysis strategies for how to access these obstacles through the use of network- and systems biology will be reviewed.
- A non-oncology clinical case study is presented, where integrative analysis of sequencing data is effectively used for patient stratification. Validation confirms the promises of NGS data - it is possible to effectively identify the responding patients, and improve the response rate in the clinical trial with 15 %.

Confirmed:
Thomas Skøt Jensen, CEO and co-founder, Intomics

intomics
from data to biology

Solution Provider Presentation

For sponsorship opportunities please contact Steve Hambrook at steve@globalengage.co.uk

16.00-16.50

Afternoon Refreshments
Poster Presentation Sessions
One to One Meetings

16.50-17.20

Solution Provider Presentation
Title to be Confirmed

ferrer inCode

Solution Provider Presentation

For sponsorship opportunities please contact Steve Hambrook at steve@globalengage.co.uk

17.20-17.50

Panel Discussion – **Future of Precision Medicine**

Confirmed:
Martina Kaufmann, Managing Director, Martina Kaufmann Strategic Consulting

Thomas Wilckens, CSO & Founder, InnVentis

Jonathan Lewis, CEO and Chairman, Molecular Ninja Therapeutics, USA

Invitation to: **Senior Representatives x2**

Variable short tandem repeat [STR] polymorphisms to identify associations related to several neurodegenerative diseases

Reserved:
Allen D. Roses, Jefferson-Pilot Distinguished Professor of Neurobiology and Neurology, Duke University & President and CEO, Zinfandel Pharmaceuticals, Inc.

17.50-18.20

From Biobanking to Precision Medicine - an Estonian Approach

- Biobanks are very useful tools to analyse the genetic variation in the population
- Extensive genotyping and sequencing together with the deep phenotyping and description of the environmental factors are prerequisites for the precision medicine
- Automated decision support software helps the primary care providers to communicate disease risks and drug response data to the people
- Finally, people need remote monitoring and coaching in order to sustain the modified lifestyle

Confirmed:
Andres Metspalu, Professor and Director Estonian Genome Center, University of Tartu, Estonia

Pharmacogenetics and Precision Medicine: Using NGS Technology to Interrogate Genetic Variants Responsible for Drug Efficacy and Drug Safety

Genetic variation largely contributes to inter-individual differences in drug responses including drug efficacy and drug safety, and understanding genetic susceptibilities to drug responses is critical to the implementation of pharmacogenetics and precision medicine. On the other hand, the revolutionary power of next-generation sequencing enables higher sensitivity in detecting genetic variants with more specificity and capability, providing enormous opportunities and potential for researchers interrogating genetic variants responsible for drug efficacy and drug safety. Using whole exome sequencing strategy we performed pharmacogenetics studies that identified genetic variants associated with efficacy of antiplatelet drugs in an Amish population. Whole genome sequencing approach provided us single-base resolution of genetic information from European patients with carbamazepine-induced skin injury and enabled us to identify causative genetic variants contributing to the disease leading to additional predictive information for the safe use of carbamazepine.

Confirmed:
Baitang Ning, Division of Systems Biology, NCTR/FDA

18.20-18.50

Fitting The Treatment to Patients: Personalized Healthcare And Molecular Information Strategies At Roche

Confirmed
Miro Venturi, Global Head Diagnostic Biomarkers, Roche

Chairman's Closing Remarks and End of Day 1

18.50-19.50

Networking Drinks Reception

Agenda Day Two – Tuesday 15th September 2015

07.00-08.30 **Breakfast Roundtable (Invitation only) – Sponsored by Eagle Genomics**

Track Chair - **David M Jackson, VP - Diagnostics / Companion Diagnostics, Arno Therapeutics, Inc – County Hall Room**

08.40-09.20 Keynote Address
Title to be Confirmed

Confirmed:
Richard Barker, Chairman of the Precision Medicine Catapult, founding Director of the Centre for the Advancement of Sustainable Medical Innovation (CASMI) and former Director General of the Association of the British Pharmaceutical Industry

09.20-10.00 Keynote Address
Synthesis and Applications of Long DNAs/RNAs/Certain Analogs
In a collaboration with Agilent Technologies, we have developed methods and instruments for the synthesis of DNA and RNA containing up to 300 nucleotides per segment. Applications include biological research on genomes, RNA for CRISPR/Cas9 applications, and data storage. Research in the Caruthers' laboratory has led to the use of boranephosphonate DNA as a useful synthon for generating analogs such as imidoamidates, amidates, triesters, phosphonates, thiophosphates, boranephosphamidates, and morpholino DNAs. Borane phosphonates have also been used to deposit, via a redox reaction, gold or silver on to DNA arrays and nanotubes as well as to identify intracellular sequences on genomes and RNA.

Confirmed:
Marvin Caruthers, Distinguished Professor of Chemistry and Biochemistry, University of Colorado

	Biomarkers & Companion Diagnostics Development To Deliver Precision Medicine **County Hall Room**	**Integrating Personal Genomics, Big Data and Bioinformatics** **Marble Arch**
	Track Chair - **David M Jackson, VP - Diagnostics / Companion Diagnostics, Arno Therapeutics, Inc**	Track Chair - **Liz Milward, A./Professor, Deputy President Academic Senate (Research), School of Biomedical Sciences and Pharmacy, University of Newcastle, Australia**
10.00-10.30	**Solution Provider Presentation** **Title to be Confirmed** COVANCE SOLUTIONS MADE REAL™	**Solution Provider Presentation** **Storing and Analysing Thousands of Human Genomes: Challenges and Opportunities** All around the world there is an explosion of large genomics projects collecting the genomic data of several thousands of individuals. The genomic data when integrated with clinical phenotypic data from electronic medical records and deep phenotyping will yield a large dataset of genotype-phenotype data. In this talk we highlight some of the challenges of scale in developing datasets of this size and how the integration and query of these vast datasets will yield new insights into the molecular basis of disease. We will provide some examples of large scale projects which are happening today, and how the data is being stored, integrated and analysed. Confirmed: **Ketan Patel, Product Strategist Precision Medicine, Oracle Health Sciences** ORACLE HEALTH SCIENCES
10.30-11.40	**Morning Refreshments** **Poster Presentation Sessions** **One to One Meetings**	
11.40-12.10	**New Era of Personalized Medicine: Strategic Regulatory Considerations in Advancing Next Generation Sequencing** Advances in science and medicine have made available new targeted therapies with great potential to address areas of unmet medical need, including rare diseases. Next Generation Sequencing (NGS) technologies enable parallel analyses for multiple mutations thereby allowing identification of potential treatment options and greater understanding of the disease. There are significant complexities involved in developing this technology and creating regulatory pathways. Learn more about the challenges and opportunities in advancing the regulatory framework for NGS and maximizing the value of medicines for patients. Confirmed: **Jennifer Dudinak, Vice President, Global Regulatory Affairs, Head, Pharma Regulatory Therapeutic Team, GlaxoSmithKline, Research and Development**	**Big Data – Title to be Confirmed** Confirmed: **Niven Narain, Co-Founder, President & CTO, Berg**

12.10-12.40	**Biomarker Discovery and Precision Medicine** • Outline and organization of Biomarker Discovery at Mayo Clinic and application of Next Generation Sequencing (NGS) in test development • Testing of prostate cancer significance at the biopsy level . We used NGS to identify five markers of cancer significance and validated them using an independent cohort. • Distinguishing independent primary tumors from intrapulmonary metastases in non–small-cell carcinoma remains a clinical dilemma with significant clinical implications. Using NGS, we developed a chromosomal rearrangement–based approach to differentiate multiple primary tumors from metastasis. • Biomarkers of targeted therapy. Using NGS we are able to identify novel targetable genes in cancer. Confirmed: **George Vasmatzis, co-director, Biomarker Discovery Program, Center for Individualized Medicine, Mayo Clinic, USA**	**From Big DATA to Precision Medicine: Tackling chronic diseases** • How to tackle polygenic chronic disease beyond genomics; longitudinal versus cohort based translational studies • The data deluge: How AI supports R&D and patient stratification: Pattern Diagnostics • SOPs, a key value driver for multi-omics guided R&D Confirmed: **Thomas Wilckens, CSO & Founder, InnVentis**
12.40-13.10	**Solution Provider Presentation** **Optimizing the Value of Human Samples for Biomarker Research with Proseek® Multiplex** Biomarker discovery is accelerating rapidly, establishing an increasingly vital role for biomarker analysis in understanding disease, developing new therapies and addressing the best treatment options to patients. Solutions for large-scale, multiplexed analysis of protein biomarkers are therefore becoming essential. Proseek® Multiplex from Olink Bioscience addresses this need. Based on our innovative Proximity Extension Assay (PEA) technology, this enables a high degree of multiplexing (simultaneous detection of 92 proteins in 96 samples) and robust analysis of thousands of samples per week with minimal sample consumption (1µl) and no compromise on data quality. Proseek Multiplex panels focus on major disease areas (oncology, inflammatory and cardiovascular diseases) and are developed together with leading experts in each field. Some case studies based on recent customer publications will be presented. Confirmed: **Dr. Andrea Ballagi, VP Sales and Marketing, Olink Bioscience** **Sponsored by Olink Bioscience** OLINK BIOSCIENCE	**Solution Provider Presentation** **Systematic Design and Development of The Quintiles Comprehensive Cancer Panel – A Case Study in Iterative Design and Validation** This presentation will discuss a case study of the design and development of the Quintiles Comprehensive Cancer Panel including: • How with proper experimental design, difficult to interrogate regions of interest (ROIs) can be revealed during the initial design and testing of custom panels. • Pilot experiments using known control material as well as the expected material for subsequent testing can provide the mechanism for characterizing panel performance including difficult regions. • An iterative design and testing scheme improved panel performance and allowed for the augmentation of content around difficult to interrogate regions of interest. Confirmed: **Vic Weigman, Associate Director of Translational Genomics, EA | Quintiles** **Tom Halsey Associate Director of Genomic Research and Development, EA | Quintiles** **Sponsored by EA | Quintiles** ea | QUINTILES
13.10-14.05	**Lunch** **One to One Meetings**	
14.05-14.20	**Solution Provider Presentation** **Title to be Confirmed** SomaLogic Confirmed: **Tony Bartlett, Director, European Commercial Operations & Collaborations, SomaLogic, Inc.**	**Solution Provider Presentation** **Digital Precision in Analysis of Tumor FFPE Specimens: The Time is Now** • Understanding current limitations associated with FFPE analysis • Technical overview of the DEPArray (TM) platform • Application of DEPArray (TM) sorted FFPE specimens to clinical assays Confirmed: **Farideh Bischoff, Executive Director of Scientific Affairs, SiliconBiosystems** silicon biosystems A MENARINI GROUP COMPANY
14.20-14.50	**Title to Be Confirmed** Confirmed: **Alain van Gool, Professor, Head Biomarkers in Personalized Healthcare, TNO, Radboud University Medical Center**	**The Virtual Patient, The Key to a Truly Personalised Medicine AND Prevention** • Virtual patient, systems medicine, patient-omics Confirmed: **Hans Lehrach, Professor, Max Planck Institute for Molecular Genetics, Germany**

14.50-15.20 **Collaborating to Deliver Personalized Medicine**

- Collaboration strategies for drug and diagnostic partnerships
- Challenges with co- developing drugs and diagnostics
- AZ's Personalized Healthcare Partnering Update

Confirmed
Nicole St Jean, Corporate Business Development, Global Product & Portfolio Strategy, AstraZeneca

Novel Computational Approach – PANOPLY : Precision Cancer Genomic Report: A Single Sample Inventory
With the advent of high throughput technologies, the quantity of 'omics' data has rapidly increased, creating the need for methodologies that can analyze complex datasets and provide interpretations that assist in decision making. We have developed PANOPLY, a novel computational approach to integrate both germline and somatic data obtained from multi-omics platforms and to analyze those data in the context of reference or control datasets.

Confirmed:
Krishna Kalari, Assistant Professor of Medical Informatics, Department of Health Sciences Research, Mayo Clinic

15.20-15.50 **Afternoon Refreshments**
Poster Presentation Sessions

15.50-16.20 **Circulating Clinical Biomarkers: From Protein to microRNA**

- Circulating protein marker discovery
- Circulating microRNA marker discovery
- Influence of blood matrices on circulating biomarker discovery

Confirmed:
Xuemei Zhao, Principal Scientist, Translational Biomarkers, Merck

Leveraging Disordered Protein Region Interfaces for Personalized Therapeutics
Recent studies indicate one-fifth to one-quarter of all disease mutations listed in the UniProt database can be mapped to intrinsically disordered regions. We have found that drug resistance across tuberculosis, multiple other bacterial genomes, and cancer are highly associated with disordered regions. Thus, these regions and their binding partners represent excellent new types of drug targets that can be personalized based on variants and drug resistance types. Here, we present an approach for discovering therapeutics that target protein interactions involving these regions. Finally, as a case study, we describe therapeutics that we discovered by this approach and subsequently validated against drug resistant tuberculosis.

Confirmed:
Gil Alterovitz, Assistant Professor, Harvard Medical School Director, BCL Faculty, CHIP, Boston Children's Hospital

16.20-16.50 **Big Data Analytics is the Daily Reality in Clinical Trials at Berg**

- Multi-omic and phenotypic data is invaluable resource for clinically actionable information in early stage human trials
- Artifical intelligence based analytics are successfully employed in predictive data analysis of patient molecular and medical data

Can we create innovative clinical trial workflows leading to companion DX discovery and proof of concept verification in phase I-II and validation in phase III?

Confirmed:
Slava Akmaev, Chief Analytics Officer, Senior Vice President, Berg Pharma

16.50 **Chairman's Closing Remarks and Conference Close**

Related Events

Microbiome R&D and Business Collaboration Forum			
	London	7-8 May 2015	www.globalengage.co.uk/microbiota.html
	San Diego	10-11 September 2015	www.globalengage.co.uk/microbiome.html
Synthetic Biology	London	20-21 October 2015	www.globalengage.co.uk/synthetic.html
qPCR/ dPCR	London	20-21 October 2015	www.globalengage.co.uk/qpcr.html
Digital Health	London	Nov 30-Dec 1 2015	www.globalengage.co.uk/digitalhealth.html
Digital Pathology	London	3-4 December 2015	www.globalengage.co.uk/digital-pathology.html
Biologics	Berlin	8-9 February 2016	www.globalengage.co.uk/biologics.html

Making a poster presentation

Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters. We also issue a poster ebook to all attendees with all abstracts in full.

Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.

In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and posters space is assigned on a first come first served basis (subject to checks and successful registration).

For further information on submission, approval and the technical poster spec, please contact: submit@globalengage.co.uk or go to www.globalengage.co.uk/precision/delegates.html

Sponsorship

Sponsorship and Exhibition opportunities available

For more details contact:
Steve Hambrook, Conference Director

steve@globalengage.co.uk
Tel +44 (0) 1865 849841